Apr 17 |
We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
|
Apr 11 |
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
|
Apr 10 |
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
|
Apr 10 |
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
|
Apr 5 |
What Makes Castle Bioscience (CSTL) a Prospective Investment?
|
Apr 4 |
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
|
Apr 2 |
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 27 |
Castle Biosciences Announces Updates to its Board of Directors
|
Mar 25 |
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
|
Mar 22 |
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
|